Back

Predictive factors for alirocumab dose increase in patients with hypercholesterolaemia and high cardiovascular risk: from the ODYSSEY COMBO I and II trials

29 August 2017 (14:00 - 18:00)
Organised by:
Congress Presentation Part of: Poster session 7 - Lipids Lipids (Epidemiology and Prevention) ESC Premium Access ESC Congress 2017

About the speaker

Photo
Doctor Antonio J Vallejo-Vaz

University of Seville, Seville (Spain)

14 More presentations in this session

Presentation thumbnail
Doctor C. Brotons (Barcelona, ES)
Abstract Slides
Presentation thumbnail
Professor N. Danchin (Paris, FR)
Abstract Slides
Presentation thumbnail
Professor G. Latkovskis (Riga, LV)
Abstract Slides
Presentation thumbnail
Associate Professor L. Drager (Sao Paulo, BR)
Abstract
Presentation thumbnail
Doctor K. Tsuda (Takatsuki, JP)
Abstract

Access the full session

Session thumbnail
Poster session 7 - Lipids

The Event

Event poster

ESC Congress 2017

29 August 2017 14:00 CET

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources